Abstract
GVHD remains the major impediment to broader application of allogeneic haematopoietic SCT. It can be prevented completely, but at the expense of other complications, rejection, relapse or delayed immune reconstitution. No optimal prevention or treatment method has been defined. This is reflected by enormous heterogeneity in approaches in Europe. Retrospective comparisons between different policies, although warranted, do not give definite answers. In order to improve the present situation, an European Group for Blood and Marrow Transplantation and the European LeukemiaNet working group has developed in a Delphi-like approach recommendations for prophylaxis and treatment of GVHD in the most common allogeneic transplant setting, transplantation from an HLA-identical sibling or unrelated donor for standard risk malignant disease. The working group proposes these guidelines to be adopted as routine standard in transplantation centres and to be used as comparator in systematic studies evaluating the advantages and disadvantages of practices differing from these recommendations.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT
Orphanet Journal of Rare Diseases Open Access 02 December 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 63: 221–230.
Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–812.
Bacigalupo A, Van Lint MT, Occhini D, Guolandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.
Ruutu T, Niederwieser D, Gratwohl A, Apperley JF, on behalf of the Chronic Leukaemia Working Party of the EBMT. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759–764.
Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J et al. Prophylaxis and treatment of graft versus host disease after haematopoietic stem cell transplantation: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 1459–1464.
Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transransplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.
Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation and donor health. Bone Marrow Transplant 2008; 42: 9–14.
Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G et al. Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data—A WBMT consensus document. Bone Marrow Transplant 2012; 48: 220–225.
Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35: 737–746.
Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 471–482.
Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger A, Frere P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011; 46: 709–718.
Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J et al. Introduction of a quality management system and outcome after hematopoietic stem cell transplantation. J Clin Oncol 2011; 29: 1980–1986.
Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150–1163.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-vs.-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Gratwohl AA, Bull MI, Graw RG Jr, Norton L, Knutsen T . Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. Acta Haematol 1978; 60: 233–242.
Gratwohl A . Folinic acid administration following MTX as prophylaxis for GVHD. Bone Marrow Transplant 2009; 44: 257.
Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.
Thomas FT, Griesedieck C, Thomas J, Carver M, Whitley T, Warren R et al. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Transplant Proc 1984; 16: 1561–1563.
Mohty M . Mechanism of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387–1394.
Penack O, Fischer L, Gentilini C, Nogal A, Muessig A, Rieger K et al. The type of ATG matters—natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transplant Immunol 2007; 18: 85–87.
Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109: 3219–3224.
Atta EH, Dias DS, Marra VL, de Azevedo AM . Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia; a single-center study. Ann Hematol 2010; 89: 851–859.
Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M et al. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol 2012; 96: 773–780 Erratum in: Int J Hematol 2013; 97: 154-155.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.
Storb R . Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia? Leukemia 2001; 15: 662–663.
Niederwieser D, Maris M, Shizuru J, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remission in patients with hematological diseases. Blood 2003; 101: 1620–1629.
Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli F et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288–2293.
Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177–4181.
Martin PJ, Inamoto Y, Flowers MED, Carpenter PA . Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant 2012; 18: 982–988.
Filipovich AH, Weisdorf D, Pavletic S, Socié G, Wingard JR, Lee SJ et al. National Institute of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611–1628.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Bone Marrow Transplant 2011; 17: 1–17.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ruutu, T., Gratwohl, A., de Witte, T. et al. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49, 168–173 (2014). https://doi.org/10.1038/bmt.2013.107
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.107
Keywords
This article is cited by
-
Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study
Bone Marrow Transplantation (2024)
-
Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro
Bone Marrow Transplantation (2023)
-
First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens
Bone Marrow Transplantation (2023)
-
Acute Graft-versus-Host Disease: An Update on New Treatment Options
Drugs (2023)
-
Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
Annals of Hematology (2023)